ER-PHARMA
ActiveSummary
ER-PHARMA has been active since 2022 and the Belgian Official Gazette contains no insolvency or warning signals. The 2025 annual accounts show equity of €55,819 and a net result of €13,994. Equity is growing by about 33% per year across the filed financial years. Its solvency ranks better than 73% of 9,643 sector peers (NACE 82, financial year 2025). The computed 12-month bankruptcy probability is below 0.1% (very low).
Articles of association
What the company does
- DurationHow long the company exists; usually unlimited, so until it is dissolved.
- Unlimited
- Registered office clauseThe region of the registered office; it decides among other things the language of official documents.
- “Vlaamse Gewest, 8500 Kortrijk,Zwevegemsestraat 67/32” (deed in Dutch)
Who represents it, and how
- Who signsWho may bind the company towards others, for example by signing a contract.
- Each director alone
- Board ruleHow the board is made up, meets and takes decisions.
- “Met of zonder beperking,bij gebrek bepaling onbepaalde duur, één of meer bestuurders,natuurlijke of rechtspersonen,al dan niet…” (deed in Dutch)“Geheel bevoegdheden aan hem,met delegatiemogelijkheid, iedere bestuurder alleen alle handelingen nodig of nuttig voor voorwerp,behalve wet…” (deed in Dutch)
Meetings and financial year
- Annual meetingWhen the shareholders meet each year, among other things to approve the annual accounts.
- 15 June at 20:00